All In Biotech

Drug Trial Radar · NCT03672175

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Nov 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 581 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

581

Actual

Start

Nov 19, 2018

Primary completion

Sep 24, 2019

Study completion Mar 17, 2020

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Sep 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase 3, multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy of SAGE-217 in the treatment of adult participants with major depressive disorder (MDD).

Conditions

  • Major Depressive Disorder

Interventions

  • SAGE-217Drug

    SAGE-217 hard gelatin capsules.

  • PlaceboDrug

    SAGE-217 matched placebo hard gelatin capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the 17-item HAM-D Total Score at Day 15Time frame: Baseline (BL), Day 15

Locations

53 sites in 1 country. Site status is shown where the registry gives one.

  • Sage Investigational Site

    Rogers, Arkansas

  • Sage Investigational Site

    Bellflower, California

  • Sage Investigational Site

    Garden Grove, California

  • Sage Investigational Site

    Glendale, California

  • Sage Investigational Site

    National City, California

  • Sage Investigational Site

    Oakland, California

  • Sage Investigational Site

    Oceanside, California

  • Sage Investigational Site

    Orange, California

  • Sage Investigational Site

    Pico Rivera, California

  • Sage Investigational Site

    Redlands, California

  • Sage Investigational Site

    San Diego, California

  • Sage Investigational Site

    Sherman Oaks, California

  • Sage Investigational Site

    Temecula, California

  • Sage Investigational Site

    Coral Springs, Florida

  • Sage Investigational Site

    Hollywood, Florida

  • Sage Investigational Site

    Jacksonville, Florida

  • Sage Investigational Site

    Lauderhill, Florida

  • Sage Investigational Site

    Maitland, Florida

  • Sage Investigational Site

    North Miami, Florida

  • Sage Investigational Site

    Orange City, Florida

  • Sage Investigational Site

    Orlando, Florida

  • Sage Investigational Site

    Orlando, Florida

  • Sage Investigational Site

    Atlanta, Georgia

  • Sage Investigational Site

    Atlanta, Georgia

  • Sage Investigational Site

    Atlanta, Georgia

  • Site Investigational Site

    Decatur, Georgia

  • Sage Investigational Site

    Skokie, Illinois

  • Sage Investigational Site

    Pikesville, Maryland

  • Sage Investigational Site

    Flowood, Mississippi

  • Sage Investigational Site

    Flowood, Mississippi

  • Sage Investigational Site

    O'Fallon, Missouri

  • Sage Investigational Site

    St Louis, Missouri

  • Sage Investigational Site

    Las Vegas, Nevada

  • Sage Investigational Site

    Berlin, New Jersey

  • Sage Investigational Site

    Jamaica, New York

  • Sage Investigational Site

    Rochester, New York

  • Sage Investigational Site

    Charlotte, North Carolina

  • Sage Investigational Site

    Cincinnati, Ohio

  • Sage Investigational Site

    Dayton, Ohio

  • Sage Investigational Site

    North Canton, Ohio

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.